Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum
Portfolio Pulse from
Daxor Corporation has expanded its BVA-100™ Blood Volume Diagnostic to two new hospital systems, enhancing its sales momentum. The company's ezBVA Lab service is gaining traction in nephrology and heart failure outpatient care.
December 18, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daxor Corporation has expanded its BVA-100™ Blood Volume Diagnostic to two new hospital systems, which is expected to boost sales and adoption in nephrology and heart failure outpatient care.
The expansion of Daxor's BVA-100™ to two new hospital systems is likely to increase sales and adoption of their technology, particularly in nephrology and heart failure outpatient care. This positive development is expected to have a favorable impact on DXR's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100